Objective Rituximab (RTX) is a chimeric monoclonal CD20-antibody. Lack of efficacy has
been suggested to be related to the presence of anti-drug antibodies (ADA). The aims of this …

Objectives Rituximab (RTX) is a chimeric monoclonal CD20-antibody. Lack of efficacy has
been suggested to be related to the presence of anti-drug antibodies (ADA). The aims of this …

Safety of rituximab in children with auto-immune diseases | Pediatric Rheumatology Skip to main
content SpringerLink Account Menu Find a journal Publish with us Track your research Search …

Objectives Rituximab (RTX), used for treatment in paediatric immune-mediated diseases,
can lead to hypogammaglobulinaemia and thus to an increased risk of infection, but data on …

Objective Rituximab (RTX), used for treatment in paediatric immune-mediated diseases, can
lead to hypogammaglobulinaemia and thus to an increased risk of infection, but data on …

Aims Rituximab is a chimeric IgG‐1 monoclonal antibody that depletes B cells, aiding in the
treatment of several conditions including autoimmune diseases. It is not licensed for use in …

Aims Rituximab is a monoclonal antibody directed against CD20, which is approved in
rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts …

Rituximab (RTX) is a chimeric monoclonal antibody that targets the CD20 antigen on B cells
and is used in various autoimmune disorders. In this study, we aimed to measure the …

Rituximab (RTX) is a chimeric monoclonal antibody that targets the CD20 antigen on B cells
and is used in various autoimmune disorders. In this study, we aimed to measure the …

Aims Rituximab, an anti-lymphocyte monoclonal antibody, is not currently licensed for use in
children but is used for treatment of a variety of conditions. The purpose of this study was to …